Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: james bravick who wrote (2811)	7/23/1999 12:43:00 PM
From: Bruce L	Respond to of 4140

THREAD IN SHOCK BUT SOME KIND OF DIALOGUE SHOULD CONTINUE Normally I would remain a lurker on this thread, but all the regulars -understandably - seem to be in shock. Still there are interesting questions - raised by the company in its CC today - that merit discussion. I too went through a similar trauma with ATIS. There the company got a positive panel recommendation, but was turned down by the FDA on procedural issues on the supporting data submitted and was required to redo its tests. Stock, as one poster noted fell initially from 15 to 5. Gradually over the following year it fell to 2 before recovering recently to 3!! It was with that parallel situation in mind that caused me to sell about a third of my holdings at the opening this morning. Is this what we have to look forward to with SNRS? Very possibly. If some of the contentions of the company are correct, however, there is the possibility of a substantial recovery by the end of the year. What, for instance, would happen to the stock if it leaked out that the FDA was in fact sympathetic to the company? Then again, it may not be realistic, in which case it would only give the company insiders an opportunity to unload while the getting is good, i.e., before it sinks below $1. As I say, there are issues worth discussing. Bruce